Auron Therapeutics is shifting the paradigm of cancer treatment to target key drivers of dysregulated differentiation and cellular plasticity in tumors. The company has built a proprietary, machine learning platform called AURigin that integrates large, multi-omic datasets from primary human tissue samples to enable a systems-biology understanding of normal cellular differentiation. This platform enables the determination of the drivers of dysregulated differentiation and cellular plasticity in cancer, which can in turn be targeted therapeutically.
